Acutus Medical, Inc. is a dynamic arrhythmia care company that has been leading the charge™️ since its establishment in 2011. Focused on biotechnology, health care, and manufacturing industries, the company is dedicated to developing distinct and innovative technologies to provide physicians and patients with improved results. Its AcQMap, AcQRef, and AcQGuide devices have obtained CE Mark and FDA clearance, offering a comprehensive range of applications. The company received a noteworthy $35.00M Post-IPO Debt investment on the 27th of April 2022 from Deerfield Management. This latest investment heralds a promising future for Acutus Medical, Inc. as it continues to make significant strides in the field of arrhythmia care.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Post-IPO Debt | $35.00M | 1 | Deerfield | 27 Apr 2022 |
Debt Financing | $70.00M | 3 | Royalties Fund | 20 Jun 2019 |
Series D | $100.00M | 8 | Opaleye Management | 20 Jun 2019 |
Series C | $75.00M | 5 | Deerfield | 22 Mar 2016 |
Series B | $26.20M | - | 30 Sep 2014 |
No recent news or press coverage available for Acutus Medical, Inc..